Año: 2020
Journal Impact Factor (JIF): 10.8490
| Categoría | Edición | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|---|
| CELL BIOLOGY | SCIE | 26/195 | Q1 | T1 | D2 |
Año: 2020
Journal Citation Indicator (JCI): 1,120
| Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
|---|---|---|---|---|---|
| CELL BIOLOGY | 48/201 | Q1 | T1 | D3 | 76,37 |
Año:
2020
CiteScore:
12,100
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Biochemistry | 26/415 | Q1 | T1 | D1 |
| Genetics | 23/325 | Q1 | T1 | D1 |
| Cell Biology | 31/279 | Q1 | T1 | D2 |
| Molecular Biology | 39/382 | Q1 | T1 | D2 |
SJR año:
2020
Factor de Impacto:
3,412
| Categoría | Posición | Cuartil | Tercil | Decil |
|---|---|---|---|---|
| Biochemistry | 19/467 | Q1 | T1 | D1 |
| Cell Biology | 30/304 | Q1 | T1 | D1 |
| Genetics | 23/364 | Q1 | T1 | D1 |
| Molecular Biology | 39/434 | Q1 | T1 | D1 |
| Agencia | Código de Proyecto |
|---|---|
| NIH | CA192656; FD005113; GM135671; GM125195 |
| Tower Cancer Research Foundation | - |
| # | Autor | Afiliación |
|---|---|---|
| 1 | Burgoyne, Adam M. | Moores Cancer Center (United States) |
| 2 | Vann, Kendra R. | University of Colorado School of Medicine (United States) |
| 3 | Joshi, Shweta | Moores Cancer Center (United States) |
| 4 | Morales, Guillermo A. | SignalRx Pharmaceuticals (United States) |
| 5 | Vega, Francisco M. | Universidad de Sevilla; Moores Cancer Center (United States) |
| 6 | Singh, Alok | Moores Cancer Center (United States) |
| 7 | Pal, Dhananjaya | Moores Cancer Center (United States) |
| 8 | Merati, Aran B. | Moores Cancer Center (United States) |
| 9 | University of Colorado School of Medicine (United States) | |
| 10 | Moores Cancer Center; SignalRx Pharmaceuticals (United States) |